Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MATTHEW D MCCOLLOUGH

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1063465284
CMS profile
3421
Location
NEW ALBANY, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$1,440.11

82 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,440.11 82

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 2; records 51–82 of 82 matching records. This page contains 32 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MATTHEW D MCCOLLOUGH

NPI 1063465284 · CMS profile ID 3421

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

NEW ALBANY, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–82 of 82 matching records. This page contains 32 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1063465284?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MATTHEW D MCCOLLOUGH, NPI 1063465284, CMS profile ID 3421. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–82 of 82 matching records. This page contains 32 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1063465284?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). MATTHEW D MCCOLLOUGH, NPI 1063465284, CMS profile ID 3421. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–82 of 82 matching records. This page contains 32 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1063465284?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
MATTHEW D MCCOLLOUGH, NPI 1063465284, CMS profile ID 3421, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–82 of 82 matching records. This page contains 32 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1063465284?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

82 matching records · $1,440.11 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 82 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–82 of 82.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Salix Pharmaceuticals, a division of Bausch Health US, LLC $20.6905/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057222697 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $3.0705/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057244447 CMS
Amgen Inc. $17.0005/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020018905 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $19.3004/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057247429 CMS
Janssen Biotech, Inc. $23.4104/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988165549 CMS
QOL Medical, LLC $14.4004/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059263055 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $16.4104/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057475421 CMS
ABBVIE INC. $26.9304/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997874303 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $16.5703/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057496457 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $16.9903/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057137753 CMS
Janssen Biotech, Inc. $19.8603/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988165539 CMS
Ardelyx, Inc. $18.0903/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052954559 CMS
GENZYME CORPORATION $23.5803/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050495529 CMS
INTERCEPT PHARMACEUTICALS, INC. $17.4103/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053825055 CMS
Takeda Pharmaceuticals U.S.A., Inc. $20.6503/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055480851 CMS
PFIZER INC. $16.1702/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050565187 CMS
Takeda Pharmaceuticals U.S.A., Inc. $14.8702/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055480843 CMS
Gilead Sciences, Inc. $14.7502/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026002251 CMS
Regeneron Healthcare Solutions, Inc. $27.3802/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999293863 CMS
Janssen Biotech, Inc. $39.5402/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988165529 CMS
Mylan Institutional Inc. $20.0002/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1039007397 CMS
GENZYME CORPORATION $18.5802/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050495521 CMS
Celgene Corporation $24.1201/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015631509 CMS
Takeda Pharmaceuticals U.S.A., Inc. $12.9501/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055480837 CMS
Ferring Pharmaceuticals Inc. $28.5001/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044203125 CMS
QOL Medical, LLC $15.2801/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059263059 CMS
ABBVIE INC. $12.5701/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997874299 CMS
ABBVIE INC. $2.9301/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997874295 CMS
ABBVIE INC. $13.1401/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997874297 CMS
Janssen Biotech, Inc. $12.7501/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988165521 CMS
Gilead Sciences, Inc. $14.7501/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026002243 CMS
GENZYME CORPORATION $19.8401/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050495487 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,304.98 103
PY2020 $385.36 26
PY2021 $1,146.64 86
PY2022 $1,272.47 84
PY2023 $1,440.11 82
PY2024 $1,052.08 54
PY2025 $351.09 20

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $88,619.45 35
PY2024 Principal investigator $265,108.36 114
PY2023 Principal investigator $8.50 1
PY2022 Principal investigator $70.00 1
PY2021 Recipient $4,750.00 2
PY2020 Recipient $1,022.84 3
PY2020 Principal investigator $54.44 2
PY2019 Recipient $2,230.31 1
PY2019 Principal investigator $24,403.25 7

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

35 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $2,457.85 12/29/2025 Non-covered Recipient Entity
Gastroenterology Hlth Prtnr
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175219200
Principal investigator 1 Janssen Research & Development, LLC $3,609.40 12/29/2025 Non-covered Recipient Entity
Gastroenterology Hlth Prtnr
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175219231
Principal investigator 1 Janssen Research & Development, LLC $2,457.85 12/29/2025 Non-covered Recipient Entity
Gastroenterology Hlth Prtnr
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175219312
Principal investigator 1 Janssen Research & Development, LLC $343.00 10/27/2025 Non-covered Recipient Entity
Gastroenterology Hlth Prtnr
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175219132
Principal investigator 1 Janssen Research & Development, LLC $3,727.00 10/27/2025 Non-covered Recipient Entity
Gastroenterology Hlth Prtnr
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175219148
Principal investigator 1 Janssen Research & Development, LLC $8,800.00 10/27/2025 Non-covered Recipient Entity
Gastroenterology Hlth Prtnr
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175219166
Principal investigator 1 Janssen Research & Development, LLC $2,457.85 10/27/2025 Non-covered Recipient Entity
Gastroenterology Hlth Prtnr
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175219245
Principal investigator 1 Janssen Research & Development, LLC $242.00 09/25/2025 Non-covered Recipient Entity
Gastroenterology Hlth Prtnr
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175219180
Principal investigator 1 Janssen Research & Development, LLC $242.00 09/25/2025 Non-covered Recipient Entity
Gastroenterology Hlth Prtnr
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175219192
Principal investigator 1 Janssen Research & Development, LLC $500.00 09/25/2025 Non-covered Recipient Entity
Gastroenterology Hlth Prtnr
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175219267
Principal investigator 1 Janssen Research & Development, LLC $242.00 09/25/2025 Non-covered Recipient Entity
Gastroenterology Hlth Prtnr
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175219294
Principal investigator 1 Janssen Research & Development, LLC $242.00 09/25/2025 Non-covered Recipient Entity
Gastroenterology Hlth Prtnr
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175219320
Principal investigator 1 Janssen Research & Development, LLC $6,500.00 09/01/2025 Non-covered Recipient Entity
Gastroenterology Hlth Prtnr
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175219139
Principal investigator 1 Janssen Research & Development, LLC $1,800.00 09/01/2025 Non-covered Recipient Entity
Gastroenterology Hlth Prtnr
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175219343
Principal investigator 1 Janssen Research & Development, LLC $500.00 08/06/2025 Non-covered Recipient Entity
Gastroenterology Hlth Prtnr
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175219110
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 08/06/2025 Non-covered Recipient Entity
Gastroenterology Hlth Prtnr
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175219115
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 08/06/2025 Non-covered Recipient Entity
Gastroenterology Hlth Prtnr
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175219259
Principal investigator 1 Janssen Research & Development, LLC $500.00 08/06/2025 Non-covered Recipient Entity
Gastroenterology Hlth Prtnr
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175219334
Principal investigator 1 Janssen Research & Development, LLC $2,457.85 07/28/2025 Non-covered Recipient Entity
Gastroenterology Hlth Prtnr
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175219080
Principal investigator 1 Janssen Research & Development, LLC $3,061.00 07/28/2025 Non-covered Recipient Entity
Gastroenterology Hlth Prtnr
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175219086
Principal investigator 1 Janssen Research & Development, LLC $2,691.00 07/28/2025 Non-covered Recipient Entity
Gastroenterology Hlth Prtnr
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175219093
Principal investigator 1 Janssen Research & Development, LLC $2,457.85 07/28/2025 Non-covered Recipient Entity
Gastroenterology Hlth Prtnr
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175219102
Principal investigator 1 Janssen Research & Development, LLC $3,609.40 06/30/2025 Non-covered Recipient Entity
Gastroenterology Hlth Prtnr
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175219123
Principal investigator 1 Janssen Research & Development, LLC $2,457.85 06/30/2025 Non-covered Recipient Entity
Gastroenterology Hlth Prtnr
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175219286
Principal investigator 1 Janssen Research & Development, LLC $2,457.85 04/28/2025 Non-covered Recipient Entity
Gastroenterology Hlth Prtnr
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175219213
Principal investigator 1 Janssen Research & Development, LLC $3,609.40 04/28/2025 Non-covered Recipient Entity
Gastroenterology Hlth Prtnr
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175219327
Principal investigator 1 Janssen Research & Development, LLC $2,457.85 04/21/2025 Non-covered Recipient Entity
Gastroenterology Hlth Prtnr
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175219071
Principal investigator 1 Janssen Research & Development, LLC $3,609.40 04/21/2025 Non-covered Recipient Entity
Gastroenterology Hlth Prtnr
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175219156
Principal investigator 1 Janssen Research & Development, LLC $2,457.85 04/21/2025 Non-covered Recipient Entity
Gastroenterology Hlth Prtnr
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175219252
Principal investigator 1 Janssen Research & Development, LLC $8,800.00 01/30/2025 Non-covered Recipient Entity
Gastroenterology Hlth Prtnr
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175219171
Principal investigator 1 Janssen Research & Development, LLC $2,457.85 01/30/2025 Non-covered Recipient Entity
Gastroenterology Hlth Prtnr
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175219208
Principal investigator 1 Janssen Research & Development, LLC $3,003.10 01/30/2025 Non-covered Recipient Entity
Gastroenterology Hlth Prtnr
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175219222
Principal investigator 1 Janssen Research & Development, LLC $3,609.40 01/30/2025 Non-covered Recipient Entity
Gastroenterology Hlth Prtnr
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175219238
Principal investigator 1 Janssen Research & Development, LLC $343.00 01/30/2025 Non-covered Recipient Entity
Gastroenterology Hlth Prtnr
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175219275
Principal investigator 1 Janssen Research & Development, LLC $2,457.85 01/27/2025 Non-covered Recipient Entity
Gastroenterology Hlth Prtnr
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175219303